Get the Stockscreener App
24.06
1.31%
0.31
After Hours:
24.06
Overview
News
Price History
Option Chain
Why FMS Down?
Discussions
Forecast
Stock Split
Dividend History
Fresenius Medical Care Ag Adr stock is traded at $24.06, with a volume of 301.91K.
It is up +1.31% in the last 24 hours and down -11.67% over the past month.
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
See More
Previous Close:
$23.75
Open:
$23.99
24h Volume:
301.91K
Relative Volume:
0.76
Market Cap:
$14.12B
Revenue:
$21.23B
Net Income/Loss:
$924.30M
P/E Ratio:
19.61
EPS:
1.2272
Net Cash Flow:
$2.22B
1W Performance:
+4.84%
1M Performance:
-11.67%
6M Performance:
-17.09%
1Y Performance:
+6.65%
1-Day Range:
$23.97
$24.20
1-Week Range:
$22.51
$24.20
52-Week Range:
$21.83
$30.46
Fresenius Medical Care Ag Adr Stock (FMS) Company Profile
Name
Fresenius Medical Care Ag Adr
Sector
Industry
Phone
-
Address
-
Compare FMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FMS
Fresenius Medical Care Ag Adr
|
24.06 | 13.77B | 21.23B | 924.30M | 2.22B | 1.2272 |
|
HCA
Hca Healthcare Inc
|
515.85 | 114.33B | 74.37B | 7.31B | 8.10B | 25.88 |
|
THC
Tenet Healthcare Corp
|
218.46 | 18.86B | 20.69B | 2.40B | 1.55B | 15.62 |
|
UHS
Universal Health Services Inc
|
243.74 | 14.81B | 16.08B | 1.20B | 1.06B | 17.82 |
|
EHC
Encompass Health Corp
|
116.19 | 11.38B | 5.51B | 494.70M | 386.40M | 4.84 |
Fresenius Medical Care Ag Adr Stock (FMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-02-25 | Downgrade | UBS | Neutral → Sell |
| Dec-02-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-06-24 | Initiated | Berenberg | Buy |
| Jan-08-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-24-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-17-23 | Upgrade | Societe Generale | Hold → Buy |
| Aug-14-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Resumed | Citigroup | Neutral |
| Jul-12-23 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | Bernstein | Mkt Perform |
| Jan-03-23 | Downgrade | Jefferies | Buy → Underperform |
| Oct-26-22 | Downgrade | Deutsche Bank | Hold → Sell |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-27-22 | Upgrade | Jefferies | Underperform → Buy |
| Feb-11-22 | Downgrade | Jefferies | Hold → Underperform |
| Nov-23-21 | Initiated | HSBC Securities | Hold |
| Nov-11-21 | Upgrade | Jefferies | Underperform → Hold |
| Feb-04-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-03-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| May-20-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-21-20 | Upgrade | Jefferies | Hold → Buy |
| Jun-20-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-26-18 | Upgrade | UBS | Neutral → Buy |
| Aug-28-18 | Upgrade | HSBC Securities | Hold → Buy |
| Jul-05-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-04-18 | Upgrade | UBS | Sell → Neutral |
| Dec-11-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-01-16 | Reiterated | RBC Capital Mkts | Sector Perform |
| Sep-06-16 | Upgrade | Citigroup | Neutral → Buy |
| Jul-08-16 | Upgrade | Jefferies | Underperform → Hold |
| Jan-04-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-04-15 | Reiterated | RBC Capital Mkts | Sector Perform |
| Sep-03-15 | Upgrade | Goldman | Neutral → Buy |
| Aug-13-15 | Downgrade | Societe Generale | Buy → Hold |
| Jul-31-15 | Reiterated | RBC Capital Mkts | Sector Perform |
| Aug-02-13 | Reiterated | Feltl & Co. | Hold |
| Jan-14-13 | Upgrade | HSBC Securities | Neutral → Overweight |
View All
Fresenius Medical Care Ag Adr Stock (FMS) Latest News
Alphabet Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
U.S. Arteriovenous Fistula Devices Market Trends Analysis Report 2025-2033: Lucrative Opportunities Stem from Rising ESRD Cases, Driving Demand for AVF Solutions - GlobeNewswire Inc.
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Fresenius Medical Care launches €500 million bond offering - Investing.com India
Living well with diabetes and beyond - Fresenius Medical Care
FMS Stock Price and Chart — NYSE:FMS - TradingView
Diabetes and Well-being: Interview with Dr. Hippen - Fresenius Medical Care
Fresenius Medical Care marks World Diabetes Day 2025: Living well with diabetes and beyond - Fresenius Medical Care
The Best Healthcare Stocks to Buy - Morningstar
FMS Stock Rises as Q3 Earnings Beat Estimates, Revenues Gain Y/Y - Finviz
Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025 - Fresenius Medical Care
Fresenius Medical Care reports strong Q3 with 8.3% revenue growth - Investing.com
Fresenius Medical Care highlights real-world advances in hemodiafiltration and AI at ASN Kidney Week 2025 - Fresenius Medical Care
Fresenius Medical Care Again Named to Top 100 Women-Led Businesses in Massachusetts - Fresenius Medical Care
Research in brief: Time on treatment - Fresenius Medical Care
Bank of America Securities downgrades Fresenius Medical Care AG & Co. KGaA (0H9X) to a Sell - The Globe and Mail
BofA Securities downgrades Fresenius Medical Care stock on volume concerns - Investing.com
Fresenius Medical Care stock rating downgraded to underperform by BofA - Investing.com South Africa
Fresenius Medical Care stock downgraded by BofA on patient volume concerns - Investing.com Nigeria
Fresenius Medical Care Appoints Joseph Turk to Management Board - The Globe and Mail
Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement - Fresenius Medical Care
Fresenius Medical Care advances its FME Reignite strategy by increasing ownership in its Value-Based Care asset and appointing a new leader for the operating segment - freseniusmedicalcare.com
Fresenius Medical Care Celebrates Nephrology Nurses Week with The CARE Award - freseniusmedicalcare.com
UBS downgrades Fresenius Medical Care to “sell,” warns on U.S. dialysis outlook - Investing.com
Fresenius Medical Care launches €600 million share buyback tranche - Investing.com
Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework - freseniusmedicalcare.com
Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025 - freseniusmedicalcare.com
Fresenius Medical Care ADR earnings beat by $0.41, revenue fell short of estimates - Investing.com Australia
Fresenius Medical Care Q2 results show revenue growth despite challenges - Investing.com
Fresenius Medical Care’s Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care - freseniusmedicalcare.com
Is The Options Market Predicting A Spike In Fresenius Medical Stock? - Barchart.com
"I’m in My Living Life Era”: Katelyn’s Double Transplant Journey - Fresenius Medical Care
Kidney transplantation and value-based care - Fresenius Medical Care
Why I love home dialysis as a HCP working in nephrology - Fresenius Medical Care
Coming Back Home: Dr. Len Usvyat Appointed as the Next Head of the Renal Research Institute - Fresenius Medical Care
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Fresenius Medical Care Ag Adr Stock (FMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):